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CEP290 (exon 41-intron 41) 5'-ATGTTTCTTCACATACCTTTTCTTT-3'. ASO was dissolved in RNase free water to make a 1 mM stock solution. 80%-90% confluent hURECs were treated with 6μl/ml of Endo-Porter (GeneTools LLC, USA) and with ASO at the final concentration of 1 μM in serum-free medium for 48 h unless otherwise stated. Cells were then fixed prior to immunocytochemistry or lysed for RNA or protein extraction.
To induce exon skipping of the intronic splice acceptor/β-galactosidase/neomycin phosphotransferase (SA-IRES-βGEO) gene trap cassette in Cep290
Gt HOM cells in vitro, an octaguanidine dendrimer-modified antisense oligonucleotide morpholino (vivo-ASO Gt ) was designed and manufactured (GeneTools LLC, USA) to target the gene trap using the following sequence: 5'ACCTGGTTGTCATGGAGGAGAAA 3'. Vivo-ASO Gt was dissolved in PBS to make a 1 mM stock solution. Cep290 Gt HOM cells at 70%-80% confluency were treated with vivo-ASO Gt at the final concentration of 10 μM in serum-free medium for 48 h. Cells were then lysed for RNA or protein extraction.
Immunofluorescence imaging of hURECs
hURECs were fixed in ice-cold methanol for 10 min. After 30 min saturation with 5% BSA in PBS, cells were incubated for 1 h at room temperature with the following primary antibodies:
rabbit anti-ARL13B (Proteintech, 17711-1-AP); rabbit anti-CEP290 (Abcam, ab 85728); mouse 
Scanning electron microscopy imaging
For SEM, samples were fixed overnight in 2% glutaraldehyde in 0.1 M Sorenson's phosphate buffer, dehydrated through a graded series of ethanol and then critical-point dried (Baltec dryer).
They were coated with 10nm of gold (Polaron coating unit) and viewed on a Tescan Vega LMU SEM operated at 8-10 kV. Images were captured and measured in a blinded fashion.
In vivo ASO treatment of Cep290 Gt/Gt animals
Vivo-ASO Gt dissolved in PBS was injected into the tail vein of 28 day old Cep290 Gt/Gt animals at a dose of 12.5 mg/Kg. 3 subsequent doses were administered at 3-4 day intervals over a period of 10 days, and tissues were collected 24 h after the final dose. Efficiency of the vivo-ASO Gt was confirmed via RT-PCR and western blot.
Tissue fixation and processing
Murine kidneys were fixed in 4% paraformaldehyde (PBS) overnight at 4°C, then washed in PBS and dehydrated in 70% Ethanol. The tissue was processed into paraffin wax using a Shandon™ Pathcentre™ automatic processor (Thermo Fisher Scientific). Tissues were sectioned on a RM2235 microtome (Leica), at a thickness of 8 µm on to Polysine™ adhesion slides (Thermo Fisher Scientific).
Histological staining
Slides were dewaxed in HistoclearII (National diagnostics), then stained with Haematoxylin/Eosin (H+E) according to the following protocol. Slides were hydrated through a series of ethanol washes (100%, 90% 70% and 50%), rinsed in water, and then in Harris's haematoxylin for 1 min. Slides were transferred into running tap water and then counterstained with 1% eosin for 1 min, rinsed in tap water, and then dehydrated. Slides were mounted in DPX mounting medium (Sigma-Aldrich) and visualised using a SCN400 Slide Scanner (Leica).
Immunofluorescence imaging of murine kidney sections
Slides were dewaxed in HistoclearII (National diagnostics), rehydrated then boiled in Citrate buffer (for antigen retrieval), pH 6.0 (2x5 min microwave at 900W). The slides were washed and subsequently blocked in 5% foetal calf serum for 1 h. Slides were incubated overnight at 4°C in the following antibodies: rabbit anti-ARL13B (Proteintech, 17711-1-AP), goat anti-Aquaporin2
(Santa Cruz Biotechnology, sc-9882). Following washes in PBS, slides were incubated at room temperature for 90 min in the following secondary antibodies: donkey anti-goat Alexa Fluor 647, donkey anti-rabbit Alexa Fluor 488 (Thermo Fisher Scientific, 1: 300). Following final washes in PBS, slides were mounted in Vectashield (Vector Laboratories Ltd, H-1200). Images were captured in a blinded fashion, using an Axio Imager Z1 fluorescent microscope (Zeiss).
Image analysis
Following capture, images were analysed using FIJI (ImageJ) software. To measure the size of cysts, 3 H+E images from each sample were set a threshold using the colour threshold function and the size of cysts calculated using the measure particles function. The resulting sum of all of the cysts was then used to calculate the cystic index, correcting for the total size of the kidney.
The length of cilia was measured using the segmented line tool on a maximum intensity projection of a z-stack.
Western blotting
Kidneys were snap frozen in liquid nitrogen and stored at -80°C. A lysis buffer solution containing 4 M urea, 125 mM Tris pH 6.8, 4% SDS, 10% glycerol, 5% β-mercaptoethanol and 0.02% bromophenol blue was used to homogenize kidney tissue or lyse hURECs and murine cells. 
RNA extraction and cDNA synthesis
RNA was extracted from hURECs and murine tissue using Trizol (Thermo Fisher Scientific)
according to the manufacturer's instructions, and quantified using a NanoDrop 2000
Spectrophotometer (Thermo Fisher Scientific). 1 ug of RNA was reverse-transcribed using an Oligo-dT primer and SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). The resulting cDNA was diluted 10-fold in nuclease-free water.
Reverse transcriptase-PCR and quantitative RT-PCR
Reverse transcriptase PCR was carried out in a 20 μl reaction volume containing the following:
1μl of each primer (10μM stock, IDT), 0.2μl dNTPs (10mM stock, Thermo Fisher Scientific), 4 μl 5X Green GoTaq® Reaction Buffer (Promega), 0.1 μl GoTaq® DNA Polymerase, 2 μl of cDNA and 11.7 μl of nuclease-free water. The following primers were used for the reactions: Quantitative analysis of SHH expression was carried out using SYBR Green PCR Master Mix 
Fig. S3. Human renal kidney sections from JBTS patients with CEP290 mutations show cilia defects
Renal biopsies from JBTS patients with cystic kidney disease secondary to CEP290 mutations.
Sections stained with antibodies directed towards cilia proteins (ARL13B, green; Alphaacetylated tubulin, red) and DAPI (blue) to identify nuclei. Defects in cilia length, with elongated and tortuous cilia (marked with*), are seen in JBTS-S1 and JBTS-S2 when compared to control.
Scale bar 10 µm. Molecular genetics confirmed CEP290 mutations in both patients: JBTS-S1
has compound heterozygous frameshift mutations c.5649-5650insA, (p.1884fsx23) and c.5850delT, (p.F1950fsx15); JBT-S2 has a homozygous missense mutation c.2915T>C, (p.L972P). , that encodes a protein consisting of 2438 amino acids (E) Schematic of predicted CEP290 amino acid sequence encoded by exons 2 to 54 (in alternating colours pink and blue) and predicted coiled coil domains (NCoils, Ensembl) aligned to each exon. Exon 41 is predicted to encode a discrete coiled coil domain from amino acids 1867-1894. The JBTS-AA mutation G1890* is marked by a red square. Skipping of this exon would remove this single predicted coiled coil domain. The CEP290 mutation database was used to determine data (https://cep290base.cmgg.be). Bars coloured green indicating a potential skippable exon, in terms of no change in reading frame. JBTS-AA mutation G1890* located in exon 41 is shown. 
